Sumitomo Dainippon Pharma Annual Report 2017
98/102

Millions of yenThousands ofU.S. dollars201620172017Millions of yenThousands ofU.S. dollars201620172017 $ (31,241)(53,143)(84,384)24,902$ (59,473)$ (98)35$ (63)$ (20,509) (20,509) $ 11,1432,93714,080(4,089)$ 9,991$ (70,054) ¥ 10,358(7,430)2,928(734)¥ 2,194¥ (22)7¥ (15)¥ (20,002)(20,002)¥ (2,929)1,221(1,708)413¥ (1,295)¥ (19,118)¥ (3,499)(5,952)(9,451)2,789¥ (6,661)¥ (11)4¥ (7)¥ (2,297)(2,297)¥ 1,2483291,577(458)¥ 1,119¥ (7,846)Unrealized gains on available-for-sale securities Amount arising during the period under review Reclassication adjustment for gains (losses) included in net income Before income tax effect adjustment Amount of income tax effect Unrealized gains on available-for-sale securities, net of taxDeferred gains or losses on hedges Amount arising during the period under review Amount of income tax effect Deferred gains or losses on hedges, net of taxForeign currency translation adjustment Amount arising during the period under review Foreign currency translation adjustmentRemeasurements of dened benet plans Amount arising during the period under review Reclassication adjustment for gains (losses) included in net income Before income tax effect adjustment Amount of income tax effect Remeasurements of dened benet plans, net of tax Total other comprehensive income (loss) $ 598 ¥ 101 ¥ 67Loans guaranteed—Employee’s housing loans guaranteedRestructuring carried out in the year ended March 31, 2017 was for the purpose of improving the business structure and organization including the early retirement program in the Company. Restructuring carried out in the year ended March 31, 2016 was for the purpose of improving the business structure and organization in the Company. 18. RESTRUCTURINGComponents of other comprehensive income (loss) for the years ended March 31, 2017 and 2016 were as follows:19. OTHER COMPREHENSIVE INCOME (LOSS)Contingent liabilities for guarantees as of March 31, 2017 and 2016 were as follows:20. CONTINGENT LIABILITIESNotes to Consolidated Financial StatementsSumitomo Dainippon Pharma Co., Ltd. and Consolidated SubsidiariesYears Ended March 31, 2017 and 2016Financial SectionSumitomo Dainippon Pharma Co., Ltd. Annual Report 201797

元のページ  ../index.html#98

このブックを見る